Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Astellas Pharma
Man Max 99 years
Astellas Pharma Global Development, Inc (APGD)
Update Il y a 4 ans
A Randomized, Double-Blind, Phase II, Efficacy and Safety Study of MDV3100 (ASP9785) vs. Bicalutamide in Castrate Men with Metastatic Prostate Cancer
To determine the PFS of MDV3100 as compared to bicalutamide
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Astellas Pharma Europe Ltd
Update Il y a 4 ans
A LONG-TERM FOLLOW UP STUDY TO EVALUATE THE SAFETY AND EFFICACY IN TRANSPLANT RECIPIENTS TREATED WITH MODIFIED RELEASE TACROLIMUS, FK506E (MR4); BASED IMMUNOSUPPRESSION REGIMEN
The objective of this study is to assess the safety and efficacy of FK506E (MR4) as long-term treatment in transplant recipients who have participated in one of the phase II PK or phase III studies on...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Astellas Pharma Europe B.V
Update Il y a 4 ans
A study to investigate efficacy and safety of Enzalutamide in patients with hormone-naïve prostate cancer
To evaluate the effect of MDV3100 on prostate-specific antigen (PSA)
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Astellas Pharma Europe B.V
Update Il y a 4 ans
Efficacy and safety of Alefacept in combination with Tacrolimus, Mycophenolate Mofetil and Steroids in de-novo kidney transplantation – a multicenter, randomized, double-blind, placebo controlled, parallel group study Short Title: Proof of Concept with Alefacept in Kidney Transplantation Protocol for Phase 2 Study of Alefacept
The primary objective of this study is to evaluate the efficacy and safety of alefacept in a kidney transplant population. Data suggests that 12 weeks of treatment with alefacept in combination with t...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Astellas Pharma Europe B.V
Update Il y a 4 ans
A trial to investigate the efficacy of ASP7692 in patients with pain due to arthritis in the knee
Evaluate the analgesic efficacy of ASP7962 relative to placebo
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Astellas Pharma Europe BV
Update Il y a 4 ans
A study in patients with overactive bladder to evaluate the efficacy, safety and tolerability of a combination of two drugs (solifenacin succinate and mirabegron) with either drug alone, and to find the best dose for each of the drugs in combination
To evaluate the efficacy of four combinations of solifenacin succinate (2.5 mg or 5 mg) plus mirabegron (25 mg or 50 mg) vs. solifenacin succinate 5 mg monotherapy.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Astellas Pharma
Update Il y a 4 ans
Étude EV-301 : étude de phase 3 randomisée comparant l’efficacité de l’enfortumab vedotin par rapport à celle du docétaxel, de la vinflunine ou du paclitaxel chez des patients ayant un cancer de l'urothélium localement avancé ou métastatique.
Le carcinome urothélial est le type le plus fréquent de cancer de la vessie, il représente plus de 90% de tous les cancers de la vessie. Le carcinome urothélial, aussi appelé carcinome transitionnel a...
Country
France
organs
Appareil urinaire - autres
,
Rein
Specialty
Chimiothérapie
,
Immunothérapie - Vaccinothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Astellas Pharma Europe Ltd
Update Il y a 4 ans
Comparison of efficacy and safety of Qutenza vs Lyrica
To compare the efficacy of QUTENZA versus pregabalin in subjects with peripheral neuropathic pain (PNP) after 8 weeks
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Astellas Pharma Europe Ltd
Update Il y a 4 ans
A MULTICENTER, SINGLE-ARM, OPEN, CONVERSION STUDY FROM A CYCLOSPORINE (CyA) BASED IMMUNOSUPPRESSIVE REGIMEN TO A TACROLIMUS MODFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRANSPLANT SUBJECTS
Primary objective is to assess the changes in kidney function in kidney transplant subjects converted from a CyA-based immunosuppressive regimen to a tacrolimus modified release, FK506E (MR4), based i...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Astellas Pharma Europe B.V
Update Il y a 4 ans
A randomized study comparing placebo and ASP3652 in the treatment of chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS)
To investigate efficacy of ASP3652 in subjects with CP/CPPS, i.e., obtain proof of concept.
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next